Anna D. Garrett, PharmD, BCPS
Anna D. Garrett is a clinical pharmacist and president of Dr. Anna Garrett (www.drannagarrett.com). Her mission is to help women in midlife maximize their mojo! Contact her at [email protected]
Less bleeding with rivaroxaban for venous thromboembolism
Studies involving more than 8,000 patients found that rivaroxaban beat out low-molecular-weight heparin/vitamin K antagonists with fewer and less challenging bleeding episodes.
Limb gangrene in cancer patients receiving warfarin
Venous limb gangrene can occur in cancer patients, but the clinical picture and pathogenesis aren’t clear.
Renal function decline common in patients treated with DOACs
Deterioration of renal function and an increase in related adverse events is not unusual in patients treated with direct oral anticoagulants.
Extending anticoagulation by 18 months lowers risk of PE recurrence
A recent study examined the benefits of extending warfarin therapy for an additional 18 months after an initial six-month treatment period.
Idarucizumab for dabigatran reversal
Results from the REVERSE-AD prospective cohort study.
Anticoagulation does not increase ICH risk in patients with brain metastases
Research results indicated that while intracranial hemorrhage is frequently observed in patients with brain metastases, treatment with low molecular weight heparin does not increase the risk.
Is digoxin a last resort in Afib?
Until another trial is conducted, digoxin use for patients who have other alternatives appears to be contraindicated.
Dual antiplatelet therapy lowers risk of CV death in MI secondary prevention
Secondary prevention of MI still calls for a careful balancing act between risks and benefits.
Warfarin does not decrease risk of stroke in dialysis patients
Oral anticoagulation therapy is the treatment of choice for clot prevention in hemodialysis patients, despite contradictory efficacy data.
Oral anticoagulation may not help all AF patients
New study finds that AF patients under 65 years of age but with a CHA2DS2-VASc score of 1 are unlikely to benefit from anticoagulation therapy.

Poll